Navigation Links
First Patient Enrolled in Global Phase III Study of Bevacizumab and Trastuzumab in Early Breast Cancer
Date:5/27/2008

Collaborative groups set out to confirm potential benefits of anticancer

therapies to treat women with breast cancer

PARIS, May 27 /PRNewswire/ -- A new international study for women with HER2-positive breast cancer is open for enrollment. The pivotal BETH (BEvacizumab and Trastuzumab Adjuvant Therapy in HER2-positive Breast Cancer) study is a Phase III clinical research trial that is investigating the benefits of combining two monoclonal antibodies, the anti-angiogenic, bevacizumab (Avastin(R)) and the targeted therapy trastuzumab (Herceptin(R)), together with chemotherapy for the treatment of patients with early stage HER2-positive breast cancer.

"Trastuzumab is already the standard of care across all stages of HER2-positive breast cancer and has a proven survival benefit. Bevacizumab has been shown to be of benefit when given in combination with chemotherapy for the treatment of metastatic breast cancer," said Dennis Slamon, MD, director of clinical/translational research at the University of California, Los Angeles' (UCLA) Jonsson Comprehensive Cancer Center and principal investigator, Cancer International Research Group. "The design of the BETH clinical trial is based on the preclinical and early clinical work from the Slamon/TRIO Laboratories at UCLA. We are looking forward to investigating the additional benefit to patients of combining these two treatments with chemotherapy in the treatment of early breast cancer."

"Despite treatment advances, over 400,000 women worldwide still die from breast cancer every year, so striving to improve treatment outcomes remains critical," said Norman Wolmark, MD, chairman of the Department of Human Oncology at the Allegheny General Hospital, and principal investigator, NSABP Foundation, Inc., Pittsburgh, Pennsylvania, USA, who welcomes the start of the study.

In BETH, patients will be randomized to a regimen of chemotherapy (either 6 cycles of docetaxel/carboplatin or 3 cycles of docetaxel, followed by 3 cycles of FEC(1)) plus trastuzumab with or without bevacizumab.

BETH was developed through the collaborative efforts of the NSABP (National Surgical Adjuvant Breast and Bowel Project) and CIRG (Cancer International Research Group). The study will be led by the two groups and will recruit approximately 3,500 patients. The primary outcome measure of BETH will be invasive disease-free survival. Secondary endpoints for the study include disease-free survival, overall survival, safety, and tolerability.

Bevacizumab and trastuzumab are used in the treatment of women with breast cancer; bevacizumab for metastatic breast cancer and trastuzumab for both early and late HER2-positive breast cancer. This is the first Phase III trial to evaluate combining the two therapies in treating early stage breast cancer.

ABOUT THE CANCER INTERNATIONAL RESEARCH GROUP (CIRG) AND TRANSLATIONAL RESEARCH IN ONCOLOGY (TRIO)

CIRG is a not-for-profit research organization with offices based in Paris, France and Alberta, Canada. With an international network of 2000 investigators and 450 cancer centers in over 45 different countries, CIRG has conducted a number of new and innovative global studies evaluating systemic therapy for cancer. The BCIRG 001 study led to the registration of docetaxel in the early breast cancer setting. The BCIRG 006 study showed that a non-anthracycline Herceptin-containing regimen was as efficacious as an anthracycline- and Herceptin-containing regimen in the early HER2-positive breast cancer setting, thus providing an equally effective, less cardiotoxic alternative to women with this type of breast cancer.

Recently, CIRG has partnered with the UCLA-based investigator network of Translational Oncology Research International, to form TRIO (Translational Research in Oncology). In addition to a network of dedicated investigators and clinical trial services, TRIO also includes the Slamon/TRIO Laboratories at UCLA. Slamon and fellow scientists have developed and adapted preclinical models which allow for the validation of molecular markers, the preclinical assessment of new biologic agents and the characterization of an agent's mechanisms of action. This preclinical work, in turn, generates the clinical hypotheses for the group's future cancer trials in patients. This translational approach has been used in the BCIRG 006 study and the newly-launched BETH clinical trial.

TRIO is dedicated to advancing translational cancer research by bringing innovative and targeted therapeutics to clinical practice. Additional information is available on the Internet at http://www.trioncology.org.

ABOUT THE NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT (NSABP)

Headquartered in Pittsburgh, Pennsylvania, USA, the National Surgical Adjuvant Breast and Bowel Project (NSABP) is a clinical trials cooperative group. The NSABP has a 50-year history of designing and conducting clinical research trials that have changed the way breast cancer is treated and, more recently, prevented.

With research sites at nearly 1,000 major medical centers, university hospitals, large oncology practice groups, and health maintenance organizations in the United States, Canada, Puerto Rico, and Ireland, the NSABP has enrolled more than 110,000 women and men in clinical trials in breast and colorectal cancer. More than 5,000 physicians, nurses, and other medical professionals conduct NSABP treatment and prevention trials.

NSABP breast cancer studies led to the establishment of lumpectomy plus radiation over radical mastectomy as the standard surgical treatment for breast cancer. In addition, the NSABP was the first to demonstrate that adjuvant therapy could alter the natural history of breast cancer, thereby increasing survival rates. The group was also the first to conduct large scale breast cancer prevention studies that showed that the drugs tamoxifen and raloxifene could reduce the risk of developing invasive breast cancer by about 50 percent in women at increased risk for the disease; more than 33,000 women participated in the Breast Cancer Prevention Trial (BCPT) and Study of Tamoxifen and Raloxifene (STAR).

Additional information about the NSABP is available on the Internet at http://www.nsabp.org.

(1) FEC refers to 5-Fluorouracil, Epirubicin, Cyclophosphamide


'/>"/>
SOURCE National Surgical Adjuvant Breast and Bowel Project
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... SPRINGS, Florida , May 25, 2016 ... Business Conference & Expo earlier this month, the numbers ... As revenues continue to climb into the billions, more ... the newly released 4th Edition State of Legal Marijuana ... Frontier, a cannabis-focused data-analysis firm, much of the increase ...
(Date:5/25/2016)... , May 25, 2016 Digital Health ... to it by the US Patent and Trademark ... technology includes proprietary processes for electronic opt-­in and ... and wellness programs, HIPAA compliance and otherwise. ... "Our technology allows for ...
(Date:5/25/2016)... , May 25, 2016 ... the precision of circulating tumour DNA (ctDNA) analysis ... the appointment of Professor Clive Morris ... leadership across the clinical development programme, scientific collaborations, ... help deliver significant improvements in clinical outcomes for ...
Breaking Medicine Technology:
(Date:5/28/2016)... ... 28, 2016 , ... May 26, 2016- In search of the K. Warriors, ... event of “K Warriors” on June 4, 2016 at Ashbury Hotel and Suites 600 ... sponsored and hosted by Shaolin Institute and sanctioned by KSF (Kungfu Sanda Federation), This ...
(Date:5/28/2016)... , ... May 28, 2016 , ... In a part of the city where’s it’s ... new farm-to-table Kelowna restaurants is hoping to attract diners with a taste for ... Suites officially opened the doors to Cornerstone Grill, an urban casual restaurant focusing on ...
(Date:5/27/2016)... ... May 27, 2016 , ... Southland Log Homes , designer ... timber frame barn kits, which can be found on its website at SouthlandLogHomes.com. , ... barn plans, and they highlight the craftsmanship of timber post and beam construction. ...
(Date:5/27/2016)... ... May 27, 2016 , ... W.S. Badger Co. ... today that it has been recognized as one of the best small businesses for ... named as one of nine small businesses providing progressive benefits to new parents on ...
(Date:5/27/2016)... ... May 27, 2016 , ... With over 60 percent ... the demand for a sustainable product to aid in the rehabilitation process has steadily ... the recovery of individuals with hemiplegia due to stroke. , Ekso Bionics has now ...
Breaking Medicine News(10 mins):